prednisone + abiraterone + cabazitaxel + enzalutamide

This is a **quadruple drug combination** used in clinical research and oncological management of metastatic castration-resistant prostate cancer (**mCRPC**). It includes: - **prednisone**, a synthetic glucocorticoid corticosteroid mainly used to prevent excess mineralocorticoid effects of abiraterone and for immunosuppression. - **abiraterone**, a CYP17 inhibitor, targeting androgen biosynthesis. - **cabazitaxel**, a semi-synthetic taxane that inhibits microtubule depolymerization, acting as a cytotoxic agent. - **enzalutamide**, a potent androgen receptor inhibitor, blocking androgen receptor signaling. This combination seeks to maximize antitumor efficacy by concurrently blocking androgen production (abiraterone), androgen receptor signaling (enzalutamide), and by adding cytotoxic effects (cabazitaxel), all under the immunomodulation of prednisone. Clinical trial evidence supports efficacy for abiraterone/prednisone + cabazitaxel, with additional studies exploring the pharmacodynamic and pharmacokinetic interactions with enzalutamide included[1][2][4][5][7][10]. Developers and manufacturers correspond to each agent’s primary company; no single developer exists for the precise four-drug combination.

Other names

prednisone + abiraterone + cabazitaxel + enzalutamide